IP Library Granted Patent US 11,174,219
Granted Patent B2
US 11,174,219 · App. 16/948,872 · Granted Nov 16, 2021

Neprilysin inhibitors

Inventors: Melissa Fleury (Brisbane, CA); Adam D. Hughes (Half Moon Bay, CA)
Assignee: Theravance Biopharma R&D IP, LLC
C07C229/22A61K31/41A61K31/415A61K31/4155A61K31/4192A61K31/4196A61K31/42A61K31/4439A61K31/675A61K45/06C07C271/22C07D207/26C07D231/14C07D231/18C07D231/20C07D249/04C07D249/12C07D249/18C07D253/08C07D257/04C07D261/18C07D263/38C07D401/04C07D405/12C07D405/14C07F9/65031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,174,219
App. No.
16/948,872
Granted
Nov 16, 2021
Kind
B2
Abstract

In one aspect, the invention relates to compounds having the formula XII: where R a , R b , R 2 , R 7 , and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Claims (24)

1. A compound selected from a compound of Formula (1), (2), (3) and (4):

or a salt thereof.

2. The compound or salt of claim 1 , wherein the compound is a compound of Formula (1).

3. The compound or salt of claim 1 , wherein the compound is a compound of Formula (2).

4. The compound or salt of claim 1 , wherein the compound is a compound of Formula (3).

5. The compound or salt of claim 1 , wherein the compound is a compound of Formula (4).

6. A method of preparing a compound of Formula (2):

comprising (i) contacting a compound of Formula (1) with trifluoroacetic acid:

7. The method of claim 6 , further comprising (ii) contacting the compound of Formula (2) with pivaloyl chloride, thereby forming a compound of Formula (3):

8. The method of claim 7 , further comprising contacting the compound of Formula (2) with sodium hydride prior to the contacting of (ii).

9. The method of claim 7 , further comprising purifying the compound of Formula (3).

10. The method of claim 7 , further comprising (iii) contacting the compound of Formula (3) with (+)-(8,8-dichlorocamphorylsulfonyl)oxaziridine, thereby forming a compound of Formula (4):

11. The method of claim 10 , further comprising contacting the compound of Formula (3) with sodium hexamethyldisilazide prior to the contacting of (iii).

12. The method of claim 10 , further comprising purifying the compound of Formula (4).

13. The method of claim 10 , further comprising (iv) contacting the compound of Formula (4) with hydrochloric acid, thereby forming a compound of the formula:

14. A method of preparing a compound of Formula (4):

comprising (iii) contacting a compound of Formula (3) with (+)-(8,8-dichlorocamphorylsulfonyl) oxaziridine:

15. The method of claim 14 , further comprising contacting the compound of Formula (3) with sodium hexamethyldisilazide prior to the contacting of (iii).

16. The method of claim 14 , further comprising purifying the compound of Formula (4).

17. The method of claim 14 , further comprising (iv) contacting the compound of Formula (4) with hydrochloric acid, thereby forming a compound of the formula:

18. The method of claim 14 , further comprising (ii) contacting a compound of Formula (2) with pivaloyl chloride:

thereby forming the compound of Formula (3).

19. The method of claim 18 , further comprising contacting the compound of Formula (2) with sodium hydride prior to the contacting of (ii).

20. The method of claim 18 , further comprising purifying the compound of Formula (3).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2026
From: THERAVANCE BIOPHARMA R&D IP, LLC
To: EONHF, INC.
Reel/Frame 075494/0756 →
Continuity (8)
Continuation 16392920 · Apr 24, 2019
Continuation 15843427 · Dec 15, 2017
Continuation 15581327 · Apr 28, 2017
Continuation 14792810 · Jul 7, 2015
Continuation 13911819 · Jun 6, 2013
Provisional Application 61773969 · Mar 7, 2013
Provisional Application 61657229 · Jun 8, 2012
Related Publication 20210155576A1 · May 27, 2021